The Use of Ibopamine in Chronic Renal Failure: Long-Term Results

Ibopamine

“…Effective renal plasma flow, creatinine clearance and glomerular filtration rate were not improved after a single oral dose of ibopamine 200mg in 15 patients, aged 54 to 74 years, with congestive heart failure, mild renal insufficiency and positive sodium balance (Kasmer et al 1990). A long term nonblinded study (3 years) showed that worsening of renal function in patients with severe renal insufficiency is consistently less in those treated with ibopamine than in non treated patients (Stefoni et al 1990). Ibopamine 100 to 150 mg/day for 7 days to 6 months also increased diuresis, renal blood flow, and electrolyte and creatinine clearance without altering heart rate, blood pressure or bodyweight in Drugs & Aging 3 (6) 1993 patients with chronic renal failure with or without concomitant congestive heart failure (Henwood & Todd 1988).…”

Low-Dosage Ibopamine Treatment in Progressive Renal Failure: A Long-Term Multicentre Trial

“…Over a period of 6 months, administration of 100 mg/ day of ibopamine to 21 patients with a mild-to-moderate degree of renal impairment resulted in more favourable renal function indexes than in a comparable control group [44], These 6-month results were confirmed by studies employing different protocols [28,29], The ibopamine capacity for slowing down the progression rate of renal impairment has also been shown in a larger patient group and over periods of treatment of up to 2 years [27].…”

“…The rate of progression is affected by a number of factors, which may also combine together [3][4][5][6][7][8][9][10][11], Hith erto various therapy strategies have been proposed [12][13][14][15], in order to slow down the speed of progression by acting on one or more of the alleged pathogenetic mecha nisms involved: treatment and prevention of intercurrent pathologies and infection episodes [9], adequate treat ment of the basal pathology [16], control of systemic arterial hypertension [17,18], low-protein and low-phos phorus diet [18][19][20], correction of dyslipaemia [21], use of platelet antiaggregants and thromboxane synthetase in hibitors [22], angiotensin-converting enzyme inhibitors [23,24], calcium antagonists [25,26], and dopamine and dopamine agonists [27][28][29], The last three drug catego ries, whatever their systemic effect, act by different mech-an isms upon glomerular haemodynamics and exert spe cific effects within the kidney [30], Various papers have dealt with the effects of antiotensin-converting enzyme inhibitors and calcium antagonists, whereas long-term experiences on dopamine and dopaminergic drugs are sel dom reported. Dopamine infused at low dosages (<5 qg/kg/min) has been used successfully in the prevention and treatment of acute renal impairment with reduced renal perfusion [31,32], The effect of dopamine is restricted to intravenous administration, however, and confined to the period of infusion itself.…”